A randomized, double-blind study of the effect of Avastin plus cisplatin and gemcitabine or placebo plus cisplatin and gemcitabine on progression-free survival in treatment-naive patients with advanced or recurrent non-squamous NSCLC.

Trial Profile

A randomized, double-blind study of the effect of Avastin plus cisplatin and gemcitabine or placebo plus cisplatin and gemcitabine on progression-free survival in treatment-naive patients with advanced or recurrent non-squamous NSCLC.

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Jul 2015

At a glance

  • Drugs Bevacizumab (Primary) ; Cisplatin; Gemcitabine
  • Indications Non-small cell lung cancer; Squamous cell cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms AVAiL
  • Sponsors Roche
  • Most Recent Events

    • 07 Jun 2011 New source identified and integrated (European Clinical Trials Database).
    • 11 Feb 2010 Final analysis published in the Annals of Oncology.
    • 30 May 2009 Final tolerability data presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO-2009).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top